---
title: "Avantor Reports Fourth Quarter and Full Year 2024 Results"
date: "2025-02-07 19:15:00"
summary: "Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, has released its financial results for the fourth fiscal quarter and the full year ended December 31, 2024. Financial Highlights For the fourth quarter of 2024, Avantor reported net..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, has released its financial results for the fourth fiscal quarter and the full year ended December 31,Â 2024.

**Financial Highlights**

For the fourth quarter of 2024, Avantor reported net sales of $1.69 billion, a decrease of 2% compared to the same period in 2023. However, on an organic basis, sales grew by 1%. The company achieved a net income of $500.4 million, significantly up from $98.5 million in the fourth quarter of 2023. Adjusted EBITDA for the quarter was $307.7 million, with an adjusted EBITDA margin of 18.2%. Diluted GAAP EPS stood at $0.73, while adjusted EPS was $0.27.

For the full year 2024, net sales were $6.78 billion, a decrease of 3% from 2023, with an organic decline of 2%. Net income for the year increased to $711.5 million from $321.1 million in 2023. Adjusted EBITDA for the year was $1.20 billion, with an adjusted EBITDA margin of 17.7%. Diluted GAAP EPS was $1.04, and adjusted EPS was $0.99.

**Business and Operational Highlights**

In the fourth quarter, Avantor's Laboratory Solutions segment reported net sales of $1.13 billion, a decrease of 5% from the previous year, with an organic sales decline of 1%. The Bioscience Production segment saw net sales of $560.8 million, an increase of 4% both on a reported and organic basis.

For the full year, Laboratory Solutions had net sales of $4.61 billion, a decrease of 3%, with an organic decline of 2%. Bioscience Production reported net sales of $2.17 billion, also a decrease of 3% on both reported and organic bases.

**Strategic Initiatives and Corporate Developments**

Avantor highlighted its cost transformation program, which is ahead of schedule, and its new operating model that is driving greater efficiency. The company also emphasized its focus on innovation-driven revenue growth, margin expansion, and continued deleveraging.

**Management's Perspective**

Michael Stubblefield, President and CEO of Avantor, commented on the results, stating, "Our fourth-quarter results highlight our team's commitment to commercial intensity, operational discipline, and enabling breakthrough therapies. We returned to growth in the fourth quarter and delivered sequential and year-over-year growth in adjusted EBITDA margin, adjusted EPS, and best-in-class free cash flow conversion."

Stubblefield also expressed confidence in achieving both near-term and long-term financial goals, citing the company's industry-leading portfolio, resilient supply chain, and relentless efficiency.

**Future Outlook**

Looking ahead, Avantor is entering the new year with strong momentum and a clear focus on innovation-driven revenue growth, margin expansion, and continued deleveraging. The company expects continued strength in its bioprocessing platform driven by focused execution and improving end market conditions.

SEC Filing: [Avantor, Inc. [ AVTR ] - 8-K - Feb. 07, 2025](https://www.sec.gov/Archives/edgar/data/1722482/000172248225000013/avtr-20250207.htm)

[TradingView](https://www.tradingview.com/news/tradingview:2c8b60132d1aa:0-avantor-reports-fourth-quarter-and-full-year-2024-results/)
